AvalehtNVON • BMV
add
Novo Nordisk A/S
Viimane sulgemishind
683,81 $
Tänane vahemik
676,00 $ - 692,00 $
Aasta vahemik
638,00 $ - 1624,38 $
Turuväärtus
128,86 mld USD
Keskmine maht
10,33 tuh
P/E suhe
-
Dividendimäär
-
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (DKK) | dets 2025info | Y/Y muutus |
|---|---|---|
Käive | 79,14 mld | −7,63% |
Põhitegevusega seonduv kulu | 29,73 mld | 12,96% |
Puhastulu | 26,89 mld | −4,74% |
Puhaskasumimarginaal | 33,98 | 3,13% |
Puhaskasum aktsia kohta | 6,04 | −4,73% |
EBITDA | 36,66 mld | −23,44% |
Tõhus maksumäär | 21,34% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (DKK) | dets 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 26,96 mld | 2,49% |
Kogu vara | 542,90 mld | 16,60% |
Kõik kohustused | 348,86 mld | 8,29% |
Kogu omakapital | 194,05 mld | — |
Emiteeritud aktsiate arv | 4,44 mld | — |
Hinna ja väärtuse suhe P/B | 15,66 | — |
Varade tasuvus | 16,70% | — |
Kapitali tasuvus | 29,56% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (DKK) | dets 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 26,89 mld | −4,74% |
Põhitegevuse rahakäive | 7,62 mld | −38,06% |
Investeeringute raha | −42,81 mld | 53,07% |
Finantseerimise raha | 29,47 mld | −20,00% |
Raha ja raha ekvivalentide muutus | −5,62 mld | 86,41% |
Tasuta rahavoog | −34,95 mld | −1 011,09% |
Teave
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Tegevjuht
Asutatud
21. dets 1923
Peakontor
Veebisait
Töötajate arv
69 150
